Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | F7 | P08709 | 3/20 | 0.65 |
| ▸ | F3 | P13726 | 3/20 | 0.65 |
| ▸ | PPARG | P37231 | 3/20 | 0.65 |
| ▸ | PPARD | Q03181 | 2/20 | 0.65 |
| ▸ | PPARA | Q07869 | 2/20 | 0.65 |
| ▸ | FABP3 | P05413 | 2/20 | 0.65 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.65 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.65 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.65 |
| ▸ | FABP4 | P15090 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477506 | 1.00 | TRPV1 (0.70) | TRPV1ALDH1A1KDM4EF7F3 | |
| SCHEMBL6472470 | 1.00 | TRPV1 (0.70) | TRPV1ALDH1A1KDM4EF7F3 | |
| SCHEMBL4750573 | 1.00 | TRPV1 (0.70) | TRPV1ALDH1A1KDM4EF7F3 | |
| SCHEMBL6473134 | 1.00 | TRPV1 (0.70) | TRPV1ALDH1A1KDM4EF7F3 | |
| SCHEMBL220462 | 1.00 | TRPV1 (0.70) | TRPV1ALDH1A1KDM4EF7F3 | |
| SCHEMBL20503612 | 1.00 | TRPV1 (0.70) | TRPV1ALDH1A1KDM4EF7F3 | |
| SCHEMBL24283496 | 1.00 | TRPV1 (0.70) | TRPV1ALDH1A1KDM4EF7F3 | |
| SCHEMBL6476959 | 1.00 | TRPV1 (0.70) | TRPV1ALDH1A1KDM4EF7F3 | |
| SCHEMBL59342 | 1.00 | TRPV1 (0.70) | TRPV1ALDH1A1KDM4EF7F3 | |
| SCHEMBL18035471 | 1.00 | TRPV1 (0.70) | TRPV1ALDH1A1KDM4EF7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096734-A1 | MICROCAPSULES | FMC CORPORATION (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4452934-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | Providence Therapeutics Holdings Inc. (CA) | 2024-10-30 | — | — | EP | disclosed |
| EP-4402121-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| US-11779911-B2 | Production of fatty olefin derivatives via olefin metathesis | PROVIVI, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| EP-4234522-A2 | PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS | Provivi, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3377465-B1 | PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS | PROVIVI INC (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023115221-A1 | IONIZABLE DILSULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023044343-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| US-20220032280-A1 | PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS | PROVIVI, INC. (US) | 2022-02-03 | — | — | US | disclosed |
| US-11077433-B2 | Production of fatty olefin derivatives via olefin metathesis | PROVIVI, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200261898-A1 | PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS | PROVIVI, INC. (US) | 2020-08-20 | — | — | US | disclosed |
| US-10596562-B2 | Production of fatty olefin derivatives via olefin metathesis | PROVIVI, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| CN-109562153-A | mRNA mediated immunization methods | 诺华股份有限公司 | 2019-04-02 | — | — | CN | disclosed |
| EP-3377465-A2 | PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS | Provivi, Inc. (US) | 2018-09-26 | — | — | EP | disclosed |
| US-20180099268-A1 | PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS | PROVIVI, INC. (US) | 2018-04-12 | — | — | US | disclosed |
| US-9776179-B2 | Production of fatty olefin derivatives via olefin metathesis | PROVIVI, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170137365-A1 | PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS | PROVIVI, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| CN-101773121-B | Sex attractant for orgyia ericae germars | SHENG MAOLING | 2013-01-09 | — | — | CN | disclosed |
| CN-101773121-A | Sex attractant for orgyia ericae germars | GUOFA CHEN | 2010-07-14 | — | — | CN | disclosed |
| WO-2005016385-A1 | INSECTICIDAL AND ACARICIDAL COMPOSITIONS WITH UV BLOCKERS AND PHEROMONES | SIRENE CALL PTY LTD (AU) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10596562-B2 | Production of fatty olefin derivatives via olefin metathesis | SREBF1, F2, SREBF2 | TRPV1 3196/4885ALDH1A1 1913/4885KDM4E 4504/4885 |
| US-20170137365-A1 | PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS | SREBF1, F2, SREBF2 | TRPV1 3196/4885ALDH1A1 1913/4885KDM4E 4504/4885 |
| US-20200261898-A1 | PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS | SREBF1, F2, SREBF2 | TRPV1 3196/4885ALDH1A1 1913/4885KDM4E 4504/4885 |
| US-11779911-B2 | Production of fatty olefin derivatives via olefin metathesis | SREBF1, F2, SREBF2 | TRPV1 3196/4885ALDH1A1 1913/4885KDM4E 4504/4885 |
| US-20180099268-A1 | PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS | SREBF1, F2, SREBF2 | TRPV1 3196/4885ALDH1A1 1913/4885KDM4E 4504/4885 |
| US-11077433-B2 | Production of fatty olefin derivatives via olefin metathesis | SREBF1, F2, SREBF2 | TRPV1 3196/4885ALDH1A1 1913/4885KDM4E 4504/4885 |
| US-20220032280-A1 | PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS | SREBF1, F2, SREBF2 | TRPV1 3196/4885ALDH1A1 1913/4885KDM4E 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.